Skip to main content
Quest Diagnostics

A Novel Factor X Variant (FX-Brockton) That Selectively Impairs Activation Via the Extrinsic Pathway

ISTH 2025

International Society on Thrombosis and Haemostasis

Washington, DC, June 21-25, 2025

Poster presentation: A Novel Factor X Variant (FX-Brockton) That Selectively Impairs Activation Via the Extrinsic Pathway

Authors: Junghans R and Wong EC

Medical Specialty: Hematology, Coagulation, Thrombosis, Cardiovascular, Genetics

Related content

Conference Presentation
The Approach to Bleeding in Patients Receiving Targeted Factor XI Therapy; Potential Role of Intravenous Hemostatic Agents/Adjuncts in Pediatric Trauma: A Review of the Evidence for (or Against) Their Use
Conference Presentation
Continued Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: Experience of a Reference Laboratory
Test FAQ
D-Dimer Quantitative
Test FAQ
Apixaban
Test FAQ
Factor VIII Activity Clotting

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.